Patents by Inventor Craig Tuerk
Craig Tuerk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7368236Abstract: The present invention includes methods for the identification and production of improved nucleic acid ligands based on the SELEX process. Also included are nucleic acid ligands to the HIV-RT protein identified according to the methods described therein.Type: GrantFiled: April 6, 2004Date of Patent: May 6, 2008Assignee: Gilead Sciences, Inc.Inventors: Larry Gold, Craig Tuerk
-
Patent number: 6933116Abstract: This invention comprises nucleic acid ligand for use as a diagnostic reagent for detecting the presence or absence of a target molecule in a sample, and a diagnostic reagent to measure the amount of a target molecule in a sample. In a preferred embodiment the nucleic acid ligands are identified by the method of the invention referred to as the Systematic Evolution of Ligands by EXponential enrichment (SELEX), wherein a candidate mixture of nucleic acids are iteratively enriched in high affinity nucleic acids and amplified by further partitioning.Type: GrantFiled: October 18, 2001Date of Patent: August 23, 2005Assignee: Gilead Sciences, Inc.Inventors: Larry Gold, Craig Tuerk
-
Publication number: 20040241731Abstract: The present invention includes methods for the identification and production of improved nucleic acid ligands based on the SELEX process. Also included are nucleic acid ligands to the HIV-RT protein identified according to the methods described therein.Type: ApplicationFiled: April 6, 2004Publication date: December 2, 2004Applicant: GILEAD SCIENCES, INC.Inventors: Larry Gold, Craig Tuerk
-
Patent number: 6716583Abstract: The present invention includes methods for the identification and production of improved nucleic acid ligands based on the SELEX process. Also included are nucleic acid ligands to the HIV-RT protein identified according to the methods described therein.Type: GrantFiled: January 7, 2002Date of Patent: April 6, 2004Assignee: Gilead Sciences, Inc.Inventors: Larry Gold, Craig Tuerk
-
Publication number: 20030198989Abstract: This invention comprises nucleic acid ligand for use as a diagnostic reagent for detecting the presence or absence of a target molecule in a sample, and a diagnostic reagent to measure the amount of a target molecule in a sample. In a preferred embodiment the nucleic acid ligands are identified by the method of the invention referred to as the Systematic Evolution of Ligands by EXponential enrichment (SELEX), wherein a candidate mixture of nucleic acids are iteratively enriched in high affinity nucleic acids and amplified by further partitioning.Type: ApplicationFiled: April 3, 2003Publication date: October 23, 2003Applicant: GILEAD SCIENCES, INC.Inventors: Larry Gold, Craig Tuerk
-
Publication number: 20030157487Abstract: This invention comprises nucleic acid ligand for use as a diagnostic reagent for detecting the presence or absence of a target molecule in a sample, and a diagnostic reagent to measure the amount of a target molecule in a sample. In a preferred embodiment the nucleic acid ligands are identified by the method of the invention referred to as the Systematic Evolution of Ligands by EXponential enrichment (SELEX), wherein a candidate mixture of nucleic acids are iteratively enriched in high affinity nucleic acids and amplified by further partitioning.Type: ApplicationFiled: October 18, 2001Publication date: August 21, 2003Inventors: Larry Gold, Craig Tuerk
-
Publication number: 20020172962Abstract: The present invention includes methods for the identification and production of improved nucleic acid ligands based on the SELEX process. Also included are nucleic acid ligands to the HIV-RT protein identified according to the methods described therein.Type: ApplicationFiled: January 7, 2002Publication date: November 21, 2002Applicant: GILEAD SCIENCES, INC.Inventors: Larry Gold, Craig Tuerk
-
Publication number: 20020038000Abstract: A method for preparing polypeptide ligands of target molecules wherein candidate mixtures comprised of ribosome complexes or mRNA&Circlesolid;polypeptide copolymers are partitioned relative to their affinity to the target and amplified to create a new candidate mixture enriched in ribosome complexes or mRNA&Circlesolid;polypeptide copolymers with an affinity to the target.Type: ApplicationFiled: February 22, 2001Publication date: March 28, 2002Inventors: Larry Gold, Craig Tuerk, David Pribnow, Jonathan Drew Smith
-
Patent number: 6344318Abstract: The present invention includes methods for the identification and production of improved nucleic acid ligands based on the SELEX process. Also included are nucleic acid ligands to the HIV-RT protein identified according to the methods described therein.Type: GrantFiled: October 2, 1998Date of Patent: February 5, 2002Assignee: Gilead Sciences, Inc.Inventors: Larry Gold, Craig Tuerk
-
Patent number: 6331398Abstract: This invention comprises nucleic acid ligand for use as a diagnostic reagent for detecting the presence or absence of a target molecule in a sample, and a diagnostic reagent to measure the amount of a target molecule in a sample. In a preferred embodiment the nucleic acid ligands are identified by the method of the invention referred to as the Systematic Evolution of Ligands by EXponential enrichment (SELEX), wherein a candidate mixture of nucleic acids are iteratively enriched in high affinity nucleic acids and amplified by further partitioning.Type: GrantFiled: February 10, 2000Date of Patent: December 18, 2001Assignee: Gilead Sciences, Inc.Inventors: Larry Gold, Craig Tuerk
-
Patent number: 6194550Abstract: A method for preparing polypeptide ligands of target molecules wherein candidate mixtures comprised of ribosome complexes or mRNA•polypeptide copolymers are partitioned relative to their affinity to the target and amplified to create a new candidate mixture enriched in ribosome complexes or mRNA•polypeptide copolymers with an affinity to the target.Type: GrantFiled: November 23, 1998Date of Patent: February 27, 2001Inventors: Larry Gold, Craig Tuerk, David Pribnow, Jonathan Drew Smith
-
Patent number: 6110900Abstract: This invention comprises nucleic acid ligand for use as a diagnostic reagent for detecting the presence or absence of a target molecule in a sample, and a diagnostic reagent to measure the amount of a target molecule in a sample. In a preferred embodiment the nucleic acid ligands are identified by the method of the invention referred to as the Systematic Evolution of Ligands by EXponential enrichment (SELEX), wherein a candidate mixture of nucleic acids are iteratively enriched in high affinity nucleic acids and amplified by further partitioning.Type: GrantFiled: August 27, 1998Date of Patent: August 29, 2000Assignee: NeXstar Pharmaceuticals, Inc.Inventors: Larry Gold, Craig Tuerk
-
Patent number: 5843653Abstract: This invention discloses a method of detecting the presence or absence of a target molecule in a sample and a method of measuring the amount of a target molecule in a sample using nucleic acid ligands. In a preferred embodiment the nucleic acid ligands are identified by the method of the invention referred to as the Systematic Evolution of Ligands by EXponential Enrichment (SELEX), wherein a candidate mixture of nucleic acids are iteratively enriched in high affinity nucleic acids and amplified for further partitioning.Type: GrantFiled: June 6, 1995Date of Patent: December 1, 1998Assignee: NeXstar Pharmaceuticals, Inc.Inventors: Larry Gold, Craig Tuerk
-
Patent number: 5843701Abstract: A method for preparing polypeptide ligands of target molecules wherein candidate mixtures comprised of ribosome complexes or mRNA.multidot.polypeptide copolymers are partitioned relative to their affinity to the target and amplified to create a new candidate mixture enriched in ribosome complexes or mRNA.multidot.polypeptide copolymers with an affinity to the target.Type: GrantFiled: January 31, 1992Date of Patent: December 1, 1998Assignee: NeXstar Pharmaceticals, Inc.Inventors: Larry Gold, Craig Tuerk, David Pribnow, Jonathan Drew Smith
-
Patent number: 5817785Abstract: The present invention includes methods for the identification and production of improved nucleic acid ligands based on the SELEX process. Also included are nucleic acid ligands to the HIV-RT protein identified according to the methods described therein.Type: GrantFiled: November 13, 1996Date of Patent: October 6, 1998Assignee: NeXstar Pharmaceuticals, Inc.Inventors: Larry Gold, Craig Tuerk
-
Patent number: 5696249Abstract: A new class of nucleic acid compounds, referred to as nucleic acid ligands, have been shown to exist that have a specific binding affinity for three dimensional molecular targets. In a preferred embodiment the ligands are identified by the method of the invention referred to as the Systematic Evolution of Ligands by EXponential enrichment (SELEX), wherein a candidate mixture of nucleic acids are iteratively enriched in high affinity nucleic acids and amplified for further partitioning.Type: GrantFiled: March 24, 1995Date of Patent: December 9, 1997Assignee: NeXstar Pharmaceuticals, Inc.Inventors: Larry Gold, Craig Tuerk
-
Patent number: 5670637Abstract: A new class of nucleic acid compounds, referred to as nucleic acid antibodies, have been shown to exist that have a specific binding affinity for three dimensional molecular targets. In a preferred embodiment the ligand components of the nucleic acid antibodies are identified by the method of the invention referred to as the Systematic Evolution of Ligands by EXponential enrichment (SELEX), wherein a candidate mixture of nucleic acids are iteratively enriched in high affinity nucleic acids and amplified for further partitioning.Type: GrantFiled: March 27, 1995Date of Patent: September 23, 1997Assignee: NeXstar Pharmaceuticals, Inc.Inventors: Larry Gold, Craig Tuerk
-
Patent number: 5637461Abstract: Methods are described for the identification of nucleic acid ligand solutions to the HIV-1 tat protein. Motifs I, II and III are nucleic acid ligands identified by the disclosed methods.Type: GrantFiled: March 24, 1995Date of Patent: June 10, 1997Assignee: NeXstar Pharmaceuticals, Inc.Inventors: Larry M. Gold, Craig Tuerk
-
Patent number: 5595877Abstract: The present invention includes methods for the identification and production of improved nucleic acid ligands based on the SELEX process. Also included are nucleic acid ligands to the HIV-RT protein identified according to the methods described therein.Type: GrantFiled: May 16, 1995Date of Patent: January 21, 1997Assignee: NeXstar Pharmaceuticals, Inc.Inventors: Larry Gold, Craig Tuerk
-
Patent number: 5527894Abstract: Methods are described for the production of nucleic acid ligands to the HIV-1 tat protein. Motifs I, II and III in FIG. 3 are nucleic acid ligands identified by the disclosed methods.Type: GrantFiled: May 17, 1994Date of Patent: June 18, 1996Assignee: NeXstar Pharmacueticals, Inc.Inventors: Larry M. Gold, Craig Tuerk